PMID- 30690795
OWN - NLM
STAT- MEDLINE
DCOM- 20200715
LR  - 20231012
IS  - 1523-4681 (Electronic)
IS  - 0884-0431 (Print)
IS  - 0884-0431 (Linking)
VI  - 34
IP  - 4
DP  - 2019 Apr
TI  - Probiotic Lactobacillus reuteri Prevents Postantibiotic Bone Loss by Reducing 
      Intestinal Dysbiosis and Preventing Barrier Disruption.
PG  - 681-698
LID - 10.1002/jbmr.3635 [doi]
AB  - Antibiotic treatment, commonly prescribed for bacterial infections, depletes and 
      subsequently causes long-term alterations in intestinal microbiota composition. 
      Knowing the importance of the microbiome in the regulation of bone density, we 
      investigated the effect of postantibiotic treatment on gut and bone health. 
      Intestinal microbiome repopulation at 4-weeks postantibiotic treatment resulted 
      in an increase in the Firmicutes:Bacteroidetes ratio, increased intestinal 
      permeability, and notably reduced femoral trabecular bone volume (approximately 
      30%, p < 0.01). Treatment with a mucus supplement (a high-molecular-weight 
      polymer, MDY-1001 [MDY]) prevented the postantibiotic-induced barrier break as 
      well as bone loss, indicating a mechanistic link between increased intestinal 
      permeability and bone loss. A link between the microbiome composition and bone 
      density was demonstrated by supplementing the mice with probiotic bacteria. 
      Specifically, Lactobacillus reuteri, but not Lactobacillus rhamnosus GG or 
      nonpathogenic Escherichia coli, reduced the postantibiotic elevation of the 
      Firmicutes:Bacteroidetes ratio and prevented femoral and vertebral trabecular 
      bone loss. Consistent with causing bone loss, postantibiotic-induced dysbiosis 
      decreased osteoblast and increased osteoclast activities, changes that were 
      prevented by both L. reuteri and MDY. These data underscore the importance of 
      microbial dysbiosis in the regulation of intestinal permeability and bone health, 
      as well as identify L. reuteri and MDY as novel therapies for preventing these 
      adverse effects. (c) 2018 American Society for Bone and Mineral Research.
CI  - (c) 2018 American Society for Bone and Mineral Research.
FAU - Schepper, Jonathan D
AU  - Schepper JD
AD  - Department of Physiology, Michigan State University, East Lansing, MI, USA.
FAU - Collins, Fraser L
AU  - Collins FL
AD  - Department of Physiology, Michigan State University, East Lansing, MI, USA.
FAU - Rios-Arce, Naiomy Deliz
AU  - Rios-Arce ND
AD  - Department of Physiology, Michigan State University, East Lansing, MI, USA.
AD  - Comparative Medicine and Integrative Biology Program, Michigan State University, 
      East Lansing, MI, USA.
FAU - Raehtz, Sandi
AU  - Raehtz S
AD  - Department of Physiology, Michigan State University, East Lansing, MI, USA.
FAU - Schaefer, Laura
AU  - Schaefer L
AD  - Department of Molecular Virology and Microbiology, Baylor College of Medicine, 
      Houston, TX, USA.
FAU - Gardinier, Joseph D
AU  - Gardinier JD
AD  - Henry Ford Health System-Bone and Joint Center, Detroit, MI, USA.
FAU - Britton, Robert A
AU  - Britton RA
AD  - Department of Molecular Virology and Microbiology, Baylor College of Medicine, 
      Houston, TX, USA.
FAU - Parameswaran, Narayanan
AU  - Parameswaran N
AD  - Department of Physiology, Michigan State University, East Lansing, MI, USA.
FAU - McCabe, Laura R
AU  - McCabe LR
AD  - Department of Physiology, Michigan State University, East Lansing, MI, USA.
LA  - eng
GR  - AT007695/National Institute of Health/International
GR  - R01 DK101050/DK/NIDDK NIH HHS/United States
GR  - R01 AT007695/AT/NCCIH NIH HHS/United States
GR  - P30 DK020572/DK/NIDDK NIH HHS/United States
GR  - RO1 DK101050/National Institute of Health/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190128
PL  - England
TA  - J Bone Miner Res
JT  - Journal of bone and mineral research : the official journal of the American 
      Society for Bone and Mineral Research
JID - 8610640
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/*adverse effects/pharmacology
MH  - Bacteroides/classification/growth & development
MH  - *Bone Resorption/chemically induced/microbiology/pathology/prevention & control
MH  - *Dysbiosis/chemically induced/microbiology/prevention & control
MH  - Firmicutes/classification/growth & development
MH  - Gastrointestinal Microbiome/*drug effects
MH  - *Limosilactobacillus reuteri
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Probiotics/*pharmacology
PMC - PMC6557403
MID - NIHMS1023688
OTO - NOTNLM
OT  - AMPICILLIN
OT  - ANTIBIOTIC
OT  - DYSBIOSIS
OT  - INTESTINAL PERMEABILITY
OT  - MICROBIOTA
OT  - OSTEOBLAST
OT  - OSTEOCLAST
OT  - TRABECULAR BONE
EDAT- 2019/01/29 06:00
MHDA- 2020/07/16 06:00
PMCR- 2020/04/01
CRDT- 2019/01/29 06:00
PHST- 2018/08/31 00:00 [received]
PHST- 2018/10/24 00:00 [revised]
PHST- 2018/11/11 00:00 [accepted]
PHST- 2019/01/29 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
PHST- 2019/01/29 06:00 [entrez]
PHST- 2020/04/01 00:00 [pmc-release]
AID - 10.1002/jbmr.3635 [doi]
PST - ppublish
SO  - J Bone Miner Res. 2019 Apr;34(4):681-698. doi: 10.1002/jbmr.3635. Epub 2019 Jan 
      28.